Clinical Trial Update: Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib to prevent acute leukemia after reduced-intensity conditioning and stem cell transplant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Biphenotypic Leukemia
• Hematopoietic Cell Transplantation Recipient
• Myelogenous Leukemia Bcr-abl1 Positive

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Andrew Rezvani | Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2023-08-01